New drug shows promise for treating blood cancer
新藥顯示出治療血癌的潛力
更新於: 2026年6月12日 上午01:30
As of June 2026, medical breakthroughs presented at the EHA and ASCO congresses are transforming blood cancer care.
截至2026年6月，在EHA與ASCO大會上發表的醫學突破正改變著血液癌症的治療。
Recent clinical trials highlight two major areas of progress: improved clinical efficacy and more practical treatment delivery.
近期的臨床試驗突顯了兩大進展方向：提升臨床療效與更便利的治療傳輸。
In terms of survival, new drug combinations are showing great potential.
在存活率方面，新的藥物組合展現了極大的潛力。
Beyond new drugs, experts are focusing on making treatments more accessible.
除了新藥，專家們正致力於使治療更易取得。
A key development is the shift toward outpatient care for advanced immunotherapies.
一項關鍵的發展是轉向門診護理以進行先進的免疫療法。
For instance, the EPCORE NHL-6 trial confirmed that epcoritamab can be safely administered outside of a hospital, allowing community oncologists to treat patients without requiring long hospital stays.
例如，EPCORE NHL-6試驗確認epcoritamab可以在醫院外安全給藥，使社區腫瘤科醫師能在不需長時間住院的情況下治療患者。
Furthermore, researchers are pushing for chemotherapy-free options, such as fixed-duration venetoclax combinations, to reduce treatment toxicity.
此外，研究人員正推動免化療的選項，例如固定療程的venetoclax組合，以降低治療毒性。
These advancements reflect a significant shift in oncology, prioritizing both the effectiveness of new therapies and the ease of access for patients globally.
這些進展反映了腫瘤學的重大轉變，優先考量新療法的有效性以及全球患者取得治療的便利性。
